Home › Glioblastoma › NCT07375992

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM) J2556

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Glioblastoma (Newly Diagnosed)
* Cognitive capacity to respond to surveys
* Access to computer and web access
* Ability to attend virtual music therapy sessions
* Audibly process music
* Proficient in English

Exclusion Criteria:

* Not planning to undergo standard of care radiation therapy and concurrent and adjuvant temozolomide.
* A life expectancy of less than 6 months.
* Concurrent use of any other standard or investigational agents (excepting tumor treating fields).
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit adherence with study requirements.

About the study

The Brain Cancer Program, in partnership with the Center for Music and Medicine at Johns Hopkins, will study whether music therapy is feasible in newly diagnosed GBM patients undergoing standard care.

What is being tested

• Music intervention (other)

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Participants: 35 · Started: May 26, 2026

Contact the study team

• Principal Investigator- Matthias Holdhoff, MD, PhD. · Phone: 410-995-8837

Official record on ClinicalTrials.gov — NCT07375992

Locations in the U.S.

Conditions

• Glioblastoma

From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.